Morgan Stanley Initiates Coverage On Immuneering with Equal-Weight Rating, Announces Price Target of $39
Morgan Stanley analyst David Lebowitz initiates coverage on Immuneering (NASDAQ:IMRX) with a Equal-Weight rating and announces Price Target of $39.